Case Report

Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient

Volume: 6 Number: 1 March 12, 2026

Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient

Abstract

Acute myeloid leukemia (AML) is a myeloid malignancy characterized by relentless proliferation of immature myeloid blasts. Myelodysplastic Syndrome (MDS)-related Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the transformation of myelodysplastic cells into an aggressive form of leukemia, marked by uncontrolled proliferation of abnormal myeloid precursors and impaired hematopoiesis. This case report delves into the intricate management and prolonged clinical success of a 77-year-old male diagnosed with MDS-related AML featuring monosomy 7, severe left ventricular ejection fraction (LVEF) heart failure, and chronic renal disease. Despite challenging laboratory findings at diagnosis and unfavorable monosomy 7 cytogenetics, the patient achieved an unexpectedly positive outcome following treatment with 5-azacytidine.This intricate case presentation not only highlights the challenges posed by advanced age, chronic disease-specific considerations, and the interplay of multiple comorbidities but also underscores the potential for tailored therapeutic interventions to transcend conventional prognostic expectations and yield prolonged clinical success.

Keywords

References

  1. 1. Kunimoto H, Fukuchi Y, Murakami K, et al. Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7. Hemasphere. 2020;17;4(5):e469. doi: 10.1097/HS9.0000000000000469.
  2. 2. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;28;72(8):1111-36. doi: 10.2165/11209430-000000000-00000.
  3. 3. Edlin R, Connock M, Tubeuf S, et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess. 2010;14(l):69-74. doi: 10.3310/hta14Suppl1/10.
  4. 4. Bouchla A, Thomopoulos TP, Papageorgiou SG, et al. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics. 2021;13(14):1129-1143. doi: 10.2217/epi-2021-0124
  5. 5. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98(7):1067-1072. doi:10.3324/haematol.2012.074831

Details

Primary Language

English

Subjects

​Internal Diseases

Journal Section

Case Report

Publication Date

March 12, 2026

Submission Date

January 21, 2025

Acceptance Date

September 9, 2025

Published in Issue

Year 2026 Volume: 6 Number: 1

APA
Ünal, S. (2026). Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient. Kastamonu Medical Journal, 6(1), 98-100. https://doi.org/10.66235/kumj.1906854
AMA
1.Ünal S. Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient. Kastamonu Medical Journal. 2026;6(1):98-100. doi:10.66235/kumj.1906854
Chicago
Ünal, Serkan. 2026. “Efficacy of 5-Azacytidine in Myelodysplastic Syndrome (MDS)-Related Acute Myeloid Leukemia (AML) With Monosomy 7: Prolonged Clinical Success in an Elderly Patient”. Kastamonu Medical Journal 6 (1): 98-100. https://doi.org/10.66235/kumj.1906854.
EndNote
Ünal S (March 1, 2026) Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient. Kastamonu Medical Journal 6 1 98–100.
IEEE
[1]S. Ünal, “Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient”, Kastamonu Medical Journal, vol. 6, no. 1, pp. 98–100, Mar. 2026, doi: 10.66235/kumj.1906854.
ISNAD
Ünal, Serkan. “Efficacy of 5-Azacytidine in Myelodysplastic Syndrome (MDS)-Related Acute Myeloid Leukemia (AML) With Monosomy 7: Prolonged Clinical Success in an Elderly Patient”. Kastamonu Medical Journal 6/1 (March 1, 2026): 98-100. https://doi.org/10.66235/kumj.1906854.
JAMA
1.Ünal S. Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient. Kastamonu Medical Journal. 2026;6:98–100.
MLA
Ünal, Serkan. “Efficacy of 5-Azacytidine in Myelodysplastic Syndrome (MDS)-Related Acute Myeloid Leukemia (AML) With Monosomy 7: Prolonged Clinical Success in an Elderly Patient”. Kastamonu Medical Journal, vol. 6, no. 1, Mar. 2026, pp. 98-100, doi:10.66235/kumj.1906854.
Vancouver
1.Serkan Ünal. Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient. Kastamonu Medical Journal. 2026 Mar. 1;6(1):98-100. doi:10.66235/kumj.1906854

Kastamonu Medical Journal is licensed under a Creative Commons CC BY-NC-ND 4.0 International License.

This is an open-access journal distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). 

Click here to get help about article submission processes and "Copyright Transfer Form".